Phase I study of bortezomib and 153Sm-lexidronam combination for refractory and relapsed multiple myeloma.

被引：0
|
作者：
Yeh, H. S.
Swift, R. A.
Ferretti, D.
Mapes, R. A.
Goeckeler, W. F.
Berenson, J. R.
机构：
[1] Inst Myeloma & Bone Canc Res, W Hollywood, CA USA
[2] Oncotheraoeut Inc, W Hollywood, CA USA
[3] Cytogen Corp, Princeton, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：450S / 450S
页数：1
相关论文
共 50 条
  • [41] A phase I MMRC clinical trial testing the combination of bortezomib and tipifarnib in relapsed/refractory multiple myeloma
    Lonial, S.
    Francis, D.
    Karanes, C.
    Trudel, S.
    Dollard, A.
    Harvey, D.
    Kaufman, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] A Phase I MMRC Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma
    Lonial, Sagar
    Francis, Dixil
    Karanes, Chatchada
    Trudel, Suzanne
    Reece, Donna E.
    Krishnan, Amrita
    Buacharem, Marc
    Smith, Renee
    Zaman, Faraz
    Gul, Engin
    Dollard, Akari M.
    Harvey, Donald
    Kaufman, Jonathan
    BLOOD, 2008, 112 (11) : 1270 - 1270
  • [43] Vorinostat in Combination with Pegylated Liposomal Doxorubicin and Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase I Study
    Voorhees, Peter M.
    Gasparetto, Cristina
    Richards, Kristy L.
    Garcia, Reynaldo
    Strader, John S.
    Ferraro, Madlyn
    MacLean, Jennifer
    Winans, Diane
    Moore, Dominic T.
    Dodd, Andrew
    Foster, Matthew C.
    Gabriel, Don A.
    Shea, Thomas C.
    Serody, Jonathan
    van Deventer, Hendrik W.
    Rizvi, Syed
    Orlowski, Robert Z.
    Hurd, David D.
    BLOOD, 2009, 114 (22) : 129 - 130
  • [44] An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma
    Alodhaibi, Ibrahim
    Ailawadhi, Sikander
    Burbano, Gabriel P.
    O'Brien, Patrick J.
    Buadi, Francis K.
    Hayman, Suzanne
    Kumar, Shaji K.
    Gonsalves, Wilson I.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (05): : 298 - 304
  • [45] Results of a Phase I Study of Vorinostat In Combination with Pegylated Liposomal Doxorubicin and Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma
    Voorhees, Peter M.
    Gasparetto, Cristina
    Osman, Keren
    Richards, Kristy
    Ferraro, Madlyn
    Garcia, Reynaldo
    MacLean, Jennifer
    Winans, Diane
    Moore, Dominic
    Strader, John
    Orlowski, Robert Z.
    Hurd, David Duane
    BLOOD, 2010, 116 (21) : 815 - 816
  • [46] Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma
    Ning, Yang-Min
    He, Kun
    Dagher, Ramz
    Sridhara, Rajeshwari
    Farrell, Ann T.
    Justice, Robert
    Pazdur, Richard
    ONCOLOGY-NEW YORK, 2007, 21 (12): : 1503 - 1508
  • [47] A phase I/II study of bortezomib and low dose intravenous melphalan (BM) for relapsed multiple myeloma.
    Popat, R
    Oakervee, HE
    Foot, N
    Agrawal, S
    Smith, P
    Craddock, C
    Williams, C
    Basu, S
    Cavenagh, JD
    BLOOD, 2005, 106 (11) : 718A - 718A
  • [48] A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma
    Ghobrial, Irene M.
    Munshi, Nikhil C.
    Harris, Brianna N.
    Shi, Peipei
    Porter, Nichole M.
    Schlossman, Robert L.
    Laubach, Jacob P.
    Anderson, Kenneth C.
    Desaiah, Durisala
    Myrand, Scott P.
    Wooldridge, James E.
    Richardson, Paul G.
    Abonour, Rafat
    AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (07) : 573 - 578
  • [49] A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma
    Yoshiaki Ogawa
    Michinori Ogura
    Kensei Tobinai
    Kiyoshi Ando
    Tatsuya Suzuki
    Takashi Watanabe
    Ken Ohmachi
    Toshiki Uchida
    Mary E. Hanson
    Yoshinobu Tanaka
    Yasuhiro Koh
    Takashi Shimamoto
    Tomomitsu Hotta
    International Journal of Hematology, 2016, 103 : 25 - 33
  • [50] A Phase I Safety Study of Enzastaurin Plus Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma
    Ghobrial, Irene M.
    Munshi, Nikhil C.
    Harris, Brianna N.
    Yuan, Zheng
    Porter, Nichole M.
    Schlossman, Robert L.
    Laubach, Jacob P.
    Anderson, Kenneth C.
    Lin, Courtney E.
    Wooldridge, James E.
    Richardson, Paul G.
    Abonour, Rafat
    BLOOD, 2009, 114 (22) : 742 - 742
12345